Jenny Chang, MD

  • Houston Methodist breast medical oncologist
  • Director, Houston Methodist Cancer Center
  • Professor of Medicine, Weill Cornell Medical College
  • Emily Herrmann Chair in Cancer Research, Houston Methodist Hospital 

Jenny Chang, MD

Areas of Expertise

  • Breast cancer
  • Cancer clinical trials
  • Cancer stem cell resistance
  • Immunotherapies and other targeted biotherapeutics
  • Metastatic breast cancer
  • Triple negative breast cancer

Credentials

BOARD CERTIFICATION
Oncology
MEDICAL SCHOOL
Cambridge University School of Clinical Medicine-Cambridge, UK | 1989
RESIDENCY
Cambridge University - Cambridge, UK
FELLOWSHIP
University of London - Medical Oncology - London, UK
Institute of Cancer Research - London, UK

Publications

MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC
Franklin, DA, Sharick, JT, Ericsson-Gonzalez, PI, Sanchez, V, Dean, PT, Opalenik, SR, Cairo, S, Judde, JG, Lewis, MT, Chang, JC, Sanders, ME, Cook, RS, Skala, MC, Bordeaux, J, Orozco Bender, J, Vaupel, C, Geiss, G, Hinerfeld, D & Balko, JM 2020, JCI insight, vol. 5, no. 15. https://doi.org/10.1172/jci.insight.134290

Emerging treatment strategies for breast cancer brain metastasis: from translational therapeutics to real-world experience
Ren, D, Cheng, H, Wang, X, Vishnoi, M, Teh, BS, Rostomily, R, Chang, JC, Wong, ST & Zhao, H 2020, , Therapeutic Advances in Medical Oncology, vol. 12. https://doi.org/10.1177/1758835920936151

Metastatic triple-negative breast cancer: Established and emerging treatments
Puri, A, Reddy, TP, Patel, TA & Chang, JC 2020, , Breast Journal, vol. 26, no. 9, pp. 1793-1796. https://doi.org/10.1111/tbj.13946

Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015
the Translational Breast Cancer Research Consortium (TBCRC) 2020, , Breast Cancer Research and Treatment, vol. 181, no. 3, pp. 623-633. https://doi.org/10.1007/s10549-020-05603-8

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer (Breast Cancer Research (2020) 22: 4 DOI: 10.1186/s13058-019-1243-8)
Goldstein, LJ, Perez, RP, Yardley, D, Han, LK, Reuben, JM, Gao, H, McCanna, S, Butler, B, Ruffini, PA, Liu, Y, Rosato, RR & Chang, JC 2020, Breast Cancer Research, vol. 22, no. 1, 52. https://doi.org/10.1186/s13058-020-01294-7

Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs
Reddy, TP, Choi, DS, Anselme, AC, Qian, W, Chen, W, Lantto, J, Horak, ID, Kragh, M, Chang, JC & Rosato, RR 2020, Breast cancer research : BCR, vol. 22, no. 1. https://doi.org/10.1186/s13058-020-01280-z

Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer
Yomtoubian, S, Lee, SB, Verma, A, Izzo, F, Markowitz, G, Choi, H, Cerchietti, L, Vahdat, L, Brown, KA, Andreopoulou, E, Elemento, O, Chang, J, Inghirami, G, Gao, D, Ryu, S & Mittal, V 2020, , Cell Reports, vol. 30, no. 3, pp. 755-770.e6. https://doi.org/10.1016/j.celrep.2019.12.056

A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer
Goldstein, LJ, Perez, RP, Yardley, D, Han, LK, Reuben, JM, Gao, H, McCanna, S, Butler, B, Ruffini, PA, Liu, Y, Rosato, RR & Chang, JC 2020, Breast Cancer Research, vol. 22, no. 1, 4. https://doi.org/10.1186/s13058-019-1243-8

The impact of molecular status on survival outcomes for invasive micropapillary carcinoma of the breast
Lewis, GD, Xing, Y, Haque, WM, Patel, T, Schwartz, MR, Chen, AC, Farach, AM, Hatch, SS, Butler, EB, Chang, JC & Teh, BS 2019, Breast Journal, vol. 25, no. 6, pp. 1171-1176. https://doi.org/10.1111/tbj.13432

Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases
Liu, ZB, Ezzedine, NE, Eterovic, AK, Ensor, Jr. JE, Huang, HJ, Albanell, J, Choi, DS, Lluch, A, Liu, Y, Rojo, F, Wong, H, Martínez-Dueñas, E, Guerrero-Zotano, Á, Shao, ZM, Darcourt, J, Mills, GB, Dave, B & Chang, JC 2019, Breast Cancer Research and Treatment, vol. 178, no. 2, pp. 251-261. https://doi.org/10.1007/s10549-019-05374-x

Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database
Lewis, GD, Xing, Y, Haque, WM, Patel, T, Schwartz, M, Chen, A, Farach, AM, Hatch, SS, Butler, EB, Chang, JC & Teh, BS 2019, , Cancer Communications, vol. 39, no. 1, 60. https://doi.org/10.1186/s40880-019-0406-4

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Patel, T, Ensor, Jr. JE, Creamer, SL, Boone, T, Rodriguez, AA, Niravath, PA, Darcourt, J, Meisel, JL, Li, X, Zhao, J, Kuhn, JG, Rosato, RR, Qian, W, Belcheva, A, Schwartz, MR, Kaklamani, VG & Chang, JC 2019, , Breast Cancer Research, vol. 21, no. 1, 100. https://doi.org/10.1186/s13058-019-1186-0

Developing a model to predict accrual to cancer clinical trials: Data from an NCI designated cancer center
Iruku, P, Goros, M, Gelfond, J, Chang, J, Padalecki, S, Mesa, R & Kaklamani, VG 2019, , Contemporary Clinical Trials Communications, vol. 15, 100421. https://doi.org/10.1016/j.conctc.2019.100421

Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression
La Belle Flynn, A, Calhoun, BC, Sharma, A, Chang, JC, Almasan, A & Schiemann, WP 2019, Nature Communications, vol. 10, no. 1, 3668. https://doi.org/10.1038/s41467-019-11640-9

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer
Veeraraghavan, J, De Angelis, C, Mao, R, Wang, T, Herrera, S, Pavlick, AC, Contreras, A, Nuciforo, P, Mayer, IA, Forero, A, Nanda, R, Goetz, MP, Chang, JC, Wolff, AC, Krop, IE, Fuqua, SAW, Prat, A, Hilsenbeck, SG, Weigelt, B, Reis-Filho, JS, Gutierrez, C, Osborne, CK, Rimawi, MF & Schiff, R 2019, Annals of Oncology, vol. 30, no. 6, mdz076, pp. 927-933. https://doi.org/10.1093/annonc/mdz076

A Deep Learning-Based Decision Support Tool for Precision Risk Assessment of Breast Cancer
He, T, Puppala, M, Ezeana, CF, Huang, Y-S, Chou, P-H, Yu, X, Chen, S, Wang, L, Yin, Z, Danforth, RL, Ensor, J, Chang, J, Patel, T & Wong, STC 2020, , JCO Clinical Cancer Informatics, vol. 3, pp. 1-12. https://doi.org/10.1200/CCI.18.00121

Erratum: Triple-negative breast cancers with amplication of JAK2 at the 9p24 locus demonstrate JAK2-specic dependence (Science Translational Medicine (2019) 11, 476, (eaaw6162), 10.1126/scitranslmed.aaw6162)
Balko, JM, Schwarz, LJ, Luo, N, Estrada, MV, Giltnane, JM, Dávila-González, D, Wang, K, Sánchez, V, Dean, PT, Combs, SE, Hicks, D, Pinto, JA, Landis, MD, Doimi, FD, Yelensky, R, Miller, VA, Stephens, PJ, Rimm, DL, Gómez, H, Chang, JC, Sanders, ME, Cook, RS & Arteaga, CL 2019, , Science translational medicine, vol. 11, no. 476, eaaw6162. https://doi.org/10.1126/scitranslmed.aaw6162

Cancer therapeutic targeting using mutant–p53-specific siRNAs
Ubby, I, Krueger, C, Rosato, R, Qian, W, Chang, J & Sabapathy, K 2019, , Oncogene, vol. 38, no. 18, pp. 3415-3427. https://doi.org/10.1038/s41388-018-0652-y

A Behavior-Modification, Clinical-Grade Mobile Application to Improve Breast Cancer Survivors' Accountability and Health Outcomes
Stubbins, R, He, T, Yu, X, Puppala, M, Ezeana, CF, Chen, S, Valdivia y Alvarado, M, Ensor, J, Rodriguez, A, Niravath, P, Chang, J, Wong, STC & Patel, T 2018, , JCO Clinical Cancer Informatics, no. 2, pp. 1-11. https://doi.org/10.1200/CCI.18.00054

Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models
Rosato, RR, Dávila-González, D, Choi, DS, Qian, W, Chen, W, Kozielski, AJ, Wong, H, Dave, B & Chang, JC 2018, , Breast Cancer Research, vol. 20, no. 1, 108. https://doi.org/10.1186/s13058-018-1037-4

Languages

  • English